Incyte Inks US$900 M Deal with MacroGenics to Develop PD-1 Inhibitor
By Jawala Prasad & Heather Cartwright
Pharma Deals Review: Vol 2017 Issue 11 (Table of Contents)
Published: 21 Nov-2017
DOI: 10.3833/pdr.v2017.i11.2284 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
US-based oncology specialist Incyte has signed an exclusive global licence agreement to develop MacroGenics’ Phase I PD-1 (programmed cell death-1) inhibitor MGA012 in a deal worth up to US$900 M, including US$150 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS